View Item 

Show simple item record

R ‐ CHOP with iodine‐131 tositumomab consolidation for advanced stage diffuse large B ‐cell lymphoma ( DLBCL ): SWOG S 0433
dc.contributor.authorFriedberg, Jonathan W.en_US
dc.contributor.authorUnger, Joseph M.en_US
dc.contributor.authorBurack, W. Richarden_US
dc.contributor.authorGopal, Ajay K.en_US
dc.contributor.authorRaju, Robert N.en_US
dc.contributor.authorNademanee, Auayporn P.en_US
dc.contributor.authorKaminski, Mark S.en_US
dc.contributor.authorLi, Honglien_US
dc.contributor.authorPress, Oliver W.en_US
dc.contributor.authorMiller, Thomas P.en_US
dc.contributor.authorFisher, Richard I.en_US
dc.date.accessioned2014-08-06T16:49:25Z
dc.date.availableWITHHELD_13_MONTHSen_US
dc.date.available2014-08-06T16:49:25Z
dc.date.issued2014-08en_US
dc.identifier.citationFriedberg, Jonathan W.; Unger, Joseph M.; Burack, W. Richard; Gopal, Ajay K.; Raju, Robert N.; Nademanee, Auayporn P.; Kaminski, Mark S.; Li, Hongli; Press, Oliver W.; Miller, Thomas P.; Fisher, Richard I. (2014). " R ‐ CHOP with iodine‐131 tositumomab consolidation for advanced stage diffuse large B ‐cell lymphoma ( DLBCL ): SWOG S 0433." British Journal of Haematology 166(3): 382-389.en_US
dc.identifier.issn0007-1048en_US
dc.identifier.issn1365-2141en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/107990
dc.publisherJohn Wiley and Sonsen_US
dc.subject.otherLymphomaen_US
dc.subject.otherChemotherapeutic Approachesen_US
dc.subject.otherDiffuse Large B Cell Lymphomaen_US
dc.subject.otherRadioimmunotherapyen_US
dc.subject.otherPharmacotherapeuticsen_US
dc.titleR ‐ CHOP with iodine‐131 tositumomab consolidation for advanced stage diffuse large B ‐cell lymphoma ( DLBCL ): SWOG S 0433en_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelOncology and Hematologyen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/107990/1/bjh12906.pdf
dc.identifier.doi10.1111/bjh.12906en_US
dc.identifier.sourceBritish Journal of Haematologyen_US
dc.identifier.citedreferenceMorschhauser, F., Kraeber‐Bodere, F., Wegener, W.A., Harousseau, J.L., Petillon, M.O., Huglo, D., Trumper, L.H., Meller, J., Pfreundschuh, M., Kirsch, C.M., Naumann, R., Kropp, J., Horne, H., Teoh, N., Le Gouill, S., Bodet‐Milin, C., Chatal, J.F. & Goldenberg, D.M. ( 2010 ) High rates of durable responses with anti‐CD22 fractionated radioimmunotherapy: results of a multicenter, phase I/II study in non‐Hodgkin's lymphoma. Journal of Clinical Oncology, 28, 3709 – 3716.en_US
dc.identifier.citedreferenceFriedberg, J.W., Kim, H., McCauley, M., Hessel, E.M., Sims, P., Fisher, D.C., Nadler, L.M., Coffman, R.L. & Freedman, A.S. ( 2005 ) Combination immunotherapy with a CpG oligonucleotide (1018 ISS) and rituximab in patients with non‐Hodgkin lymphoma: increased interferon‐alpha/beta‐inducible gene expression, without significant toxicity. Blood, 105, 489 – 495.en_US
dc.identifier.citedreferenceFriedberg, J.W., Kelly, J.L., Neuberg, D., Peterson, D.R., Kutok, J.L., Salloum, R., Brenn, T., Fisher, D.C., Ronan, E., Dalton, V., Rich, L., Marquis, D., Sims, P., Rothberg, P.G., Liesveld, J., Fisher, R.I., Coffman, R., Mosmann, T. & Freedman, A.S. ( 2009 ) Phase II study of a TLR‐9 agonist (1018 ISS) with rituximab in patients with relapsed or refractory follicular lymphoma. British Journal of Haematology, 146, 282 – 291.en_US
dc.identifier.citedreferenceGopal, A.K., Press, O.W., Wilbur, S.M., Maloney, D.G. & Pagel, J.M. ( 2008 ) Rituximab blocks binding of radiolabeled anti‐CD20 antibodies (Ab) but not radiolabeled anti‐CD45 Ab. Blood, 112, 830 – 835.en_US
dc.identifier.citedreferenceGreen, D.J., Pagel, J.M., Pantelias, A., Hedin, N., Lin, Y., Wilbur, D.S., Gopal, A., Hamlin, D.K. & Press, O.W. ( 2007 ) Pretargeted radioimmunotherapy for B‐cell lymphomas. Clinical Cancer Research, 13 ( 18 Pt 2 ), 5598s – 5603s.en_US
dc.identifier.citedreferenceGreen, T.M., Young, K.H., Visco, C., Xu‐Monette, Z.Y., Orazi, A., Go, R.S., Nielsen, O., Gadeberg, O.V., Mourits‐Andersen, T., Frederiksen, M., Pedersen, L.M. & Moller, M.B. ( 2012 ) Immunohistochemical double‐hit score is a strong predictor of outcome in patients with diffuse large B‐cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. Journal of Clinical Oncology, 30, 3460 – 3467.en_US
dc.identifier.citedreferenceHamlin, P.A. Jr, Rodriguez, M.A., Noy, A., Portlock, C.S., Straus, D., McLaughlin, P., Pro, B., Fayad, L., Hagemeister, F., Wegner, B., Dumitrescu, O., Tasker, N.P., Moskowitz, C.H. & Zelenetz, A.D. ( 2010 ) Final results of a phase II study of sequential R‐CHOP and Yttrium‐90 ibritumomab tiuxetan (RIT) for elderly high risk patients with untreated diffuse large B‐cell lymphoma (DLBCL). Blood, 116, 1793.en_US
dc.identifier.citedreferenceHans, C.P., Weisenburger, D.D., Greiner, T.C., Gascoyne, R.D., Delabie, J., Ott, G., Muller‐Hermelink, H.K., Campo, E., Braziel, R.M., Jaffe, E.S., Pan, Z., Farinha, P., Smith, L.M., Falini, B., Banham, A.H., Rosenwald, A., Staudt, L.M., Connors, J.M., Armitage, J.O. & Chan, W.C. ( 2004 ) Confirmation of the molecular classification of diffuse large B‐cell lymphoma by immunohistochemistry using a tissue microarray. Blood, 103, 275 – 282.en_US
dc.identifier.citedreferenceJohnson, N.A., Slack, G.W., Savage, K.J., Connors, J.M., Ben‐Neriah, S., Rogic, S., Scott, D.W., Tan, K.L., Steidl, C., Sehn, L.H., Chan, W.C., Iqbal, J., Meyer, P.N., Lenz, G., Wright, G., Rimsza, L.M., Valentino, C., Brunhoeber, P., Grogan, T.M., Braziel, R.M., Cook, J.R., Tubbs, R.R., Weisenburger, D.D., Campo, E., Rosenwald, A., Ott, G., Delabie, J., Holcroft, C., Jaffe, E.S., Staudt, L.M. & Gascoyne, R.D. ( 2012 ) Concurrent expression of MYC and BCL2 in diffuse large B‐cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. Journal of Clinical Oncology, 30, 3452 – 3459.en_US
dc.identifier.citedreferenceKaplan, E. & Meier, P. ( 1958 ) Nonparametric estimation from incomplete observations. Journal of the Americal Statistical Association, 53, 457 – 481.en_US
dc.identifier.citedreferenceLawless, J.F. ( 1982 ). Statistical Models and Methods for Lifetime Data. John Wiley and Sons, New York, NY.en_US
dc.identifier.citedreferenceLenz, G., Wright, G., Dave, S.S., Xiao, W., Powell, J., Zhao, H., Xu, W., Tan, B., Goldschmidt, N., Iqbal, J., Vose, J., Bast, M., Fu, K., Weisenburger, D.D., Greiner, T.C., Armitage, J.O., Kyle, A., May, L., Gascoyne, R.D., Connors, J.M., Troen, G., Holte, H., Kvaloy, S., Dierickx, D., Verhoef, G., Delabie, J., Smeland, E.B., Jares, P., Martinez, A., Lopez‐Guillermo, A., Montserrat, E., Campo, E., Braziel, R.M., Miller, T.P., Rimsza, L.M., Cook, J.R., Pohlman, B., Sweetenham, J., Tubbs, R.R., Fisher, R.I., Hartmann, E., Rosenwald, A., Ott, G., Muller‐Hermelink, H.K., Wrench, D., Lister, T.A., Jaffe, E.S., Wilson, W.H., Chan, W.C. & Staudt, L.M., Lymphoma/Leukemia Molecular Profiling ( 2008 ) Stromal gene signatures in large‐B‐cell lymphomas. New England Journal of Medicine, 359, 2313 – 2323.en_US
dc.identifier.citedreferenceMiller, T.P., Unger, J.M., Spier, C., Stea, B., Press, O.W., Friedberg, J.W., LeBlanc, M. & Fisher, R.I. ( 2008 ) Effect of adding ibritumomab tiuxetan (Zevalin) radioimmunotherapy consolidation to three cycles of CHOP plus involved‐field radiotherapy for limited‐stage aggressive diffuse B‐cell lymphoma (SWOG 0313). Blood, 112, 3598.en_US
dc.identifier.citedreferenceMorschhauser, F., Illidge, T., Huglo, D., Martinelli, G., Paganelli, G., Zinzani, P.L., Rule, S., Liberati, A.M., Milpied, N., Hess, G., Stein, H., Kalmus, J. & Marcus, R. ( 2007 ) Efficacy and safety of yttrium‐90 ibritumomab tiuxetan in patients with relapsed or refractory diffuse large B‐cell lymphoma not appropriate for autologous stem‐cell transplantation. Blood, 110, 54 – 58.en_US
dc.identifier.citedreferencePfreundschuh, M. ( 2012 ) Growing importance of MYC/BCL2 immunohistochemistry in diffuse large B‐cell lymphomas. Journal of Clinical Oncology, 30, 3433 – 3435.en_US
dc.identifier.citedreferencePfreundschuh, M., Trumper, L., Osterborg, A., Pettengell, R., Trneny, M., Imrie, K., Ma, D., Gill, D., Walewski, J., Zinzani, P.L., Stahel, R., Kvaloy, S., Shpilberg, O., Jaeger, U., Hansen, M., Lehtinen, T., Lopez‐Guillermo, A., Corrado, C., Scheliga, A., Milpied, N., Mendila, M., Rashford, M., Kuhnt, E. & Loeffler, M. ( 2006 ) CHOP‐like chemotherapy plus rituximab versus CHOP‐like chemotherapy alone in young patients with good‐prognosis diffuse large‐B‐cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncology, 7, 379 – 391.en_US
dc.identifier.citedreferencePfreundschuh, M., Schubert, J., Ziepert, M., Schmits, R., Mohren, M., Lengfelder, E., Reiser, M., Nickenig, C., Clemens, M., Peter, N., Bokemeyer, C., Eimermacher, H., Ho, A., Hoffmann, M., Mertelsmann, R., Trumper, L., Balleisen, L., Liersch, R., Metzner, B., Hartmann, F., Glass, B., Poeschel, V., Schmitz, N., Ruebe, C., Feller, A.C. & Loeffler, M., German High‐Grade Non‐Hodgkin Lymphoma Study ( 2008 ) Six versus eight cycles of bi‐weekly CHOP‐14 with or without rituximab in elderly patients with aggressive CD20 +  B‐cell lymphomas: a randomised controlled trial (RICOVER‐60). Lancet Oncology, 9, 105 – 116.en_US
dc.identifier.citedreferencePress, O.W., Unger, J.M., Braziel, R.M., Maloney, D.G., Miller, T.P., LeBlanc, M., Gaynor, E.R., Rivkin, S.E. & Fisher, R.I. ( 2003 ) A phase 2 trial of CHOP chemotherapy followed by tositumomab/iodine I 131 tositumomab for previously untreated follicular non‐Hodgkin lymphoma: Southwest Oncology Group Protocol S9911. Blood, 102, 1606 – 1612.en_US
dc.identifier.citedreferencePress, O.W., Unger, J.M., Braziel, R.M., Maloney, D.G., Miller, T.P., Leblanc, M. & Fisher, R.I., Southwest Oncology ( 2006 ) Phase II trial of CHOP chemotherapy followed by tositumomab/iodine I‐131 tositumomab for previously untreated follicular non‐Hodgkin's lymphoma: five‐year follow‐up of Southwest Oncology Group Protocol S9911. Journal of Clinical Oncology, 24, 4143 – 4149.en_US
dc.identifier.citedreferencePress, O.W., Unger, J.M., Rimsza, L.M., Friedberg, J.W., LeBlanc, M., Czuczman, M.S., Kaminski, M., Braziel, R.M., Spier, C., Gopal, A.K., Maloney, D.G., Cheson, B.D., Dakhil, S.R., Miller, T.P. & Fisher, R.I. ( 2013 ) Phase III randomized intergroup trial of CHOP plus rituximab compared with CHOP chemotherapy plus (131)iodine‐tositumomab for previously untreated follicular non‐Hodgkin lymphoma: SWOG S0016. Journal of Clinical Oncology, 31, 314 – 320.en_US
dc.identifier.citedreferenceSchaefer‐Cutillo, J. & Friedberg, J.W. ( 2008 ) Non‐myeloablative radioimmunotherapy for non‐Hodgkin's lymphoma. Seminars in Hematology, 45, 110 – 117.en_US
dc.identifier.citedreferenceStiff, P.J., Unger, J.M., Cook, J.R., Constine, L.S., Couban, S., Stewart, D.A., Shea, T.C., Porcu, P., Winter, J.N., Kahl, B.S., Miller, T.P., Tubbs, R.R., Marcellus, D., Friedberg, J.W., Barton, K.P., Mills, G.M., LeBlanc, M., Rimsza, L.M., Forman, S.J. & Fisher, R.I. ( 2013 ) Autologous transplantation as consolidation for aggressive non‐Hodgkin's lymphoma. New England Journal of Medicine, 369, 1681 – 1690.en_US
dc.identifier.citedreferenceVose, J.M., Carter, S., Burns, L.J., Ayala, E., Press, O.W., Moskowitz, C.H., Stadtmauer, E.A., Mineshi, S., Ambinder, R., Fenske, T., Horowitz, M., Fisher, R. & Tomblyn, M. ( 2013 ) Phase III randomized study of rituximab/carmustine, etoposide, cytarabine, and melphalan (BEAM) compared with iodine‐131 tositumomab/BEAM with autologous hematopoietic cell transplantation for relapsed diffuse large B‐cell lymphoma: results from the BMT CTN 0401 trial. Journal of Clinical Oncology, 31, 1662 – 1668.en_US
dc.identifier.citedreferenceWitzig, T.E., Wiseman, G.A., Maurer, M.J., Habermann, T.M., Micallef, I.N., Nowakowski, G.S., Ansell, S.M., Colgan, J.P., Inwards, D.J., Porrata, L.F., Link, B.K., Zent, C.S., Johnston, P.B., Shanafelt, T.D., Allmer, C., Asmann, Y.W., Gupta, M., Ballas, Z.K., Smith, B.J. & Weiner, G.J. ( 2013 ) A phase I trial of immunostimulatory CpG 7909 oligodeoxynucleotide and 90 yttrium ibritumomab tiuxetan radioimmunotherapy for relapsed B‐cell non‐Hodgkin lymphoma. American Journal of Hematology, 88, 589 – 593.en_US
dc.identifier.citedreferenceYounes, A., Flinn, I., Berdeja, J.G., Friedberg, J.W., Alberti, S., Thieblemont, C., Morschhauser, F., Hellemans, P., Hall, B., Smit, J., Skee, D., de Vries, R., Todorovic, M., Khan, I., Fourneau, N. & Oki, Y. ( 2013 ) Phase Ib study combining ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R‐CHOP) in patients with CD20‐positive B‐cell non‐Hodgkin lymphoma (NHL). Journal of Clinical Oncology, 31 ( Suppl. 15 ), 8502.en_US
dc.identifier.citedreferenceZiepert, M., Hasenclever, D., Kuhnt, E., Glass, B., Schmitz, N., Pfreundschuh, M. & Loeffler, M. ( 2010 ) Standard International prognostic index remains a valid predictor of outcome for patients with aggressive CD20 +  B‐cell lymphoma in the rituximab era. Journal of Clinical Oncology, 28, 2373 – 2380.en_US
dc.identifier.citedreferenceZinzani, P.L., Tani, M., Fanti, S., Stefoni, V., Musuraca, G., Castellucci, P., Marchi, E., Farsad, M., Fina, M., Pellegrini, C., Alinari, L., Derenzini, E., de Vivo, A., Bacci, F., Pileri, S. & Baccarani, M. ( 2008 ) A phase II trial of CHOP chemotherapy followed by yttrium 90 ibritumomab tiuxetan (Zevalin) for previously untreated elderly diffuse large B‐cell lymphoma patients. Annals of Oncology, 19, 769 – 773.en_US
dc.identifier.citedreferenceZinzani, P.L., Rossi, G., Franceschetti, S., Botto, B., Di Rocco, A., Cabras, M.G., Petti, M.C., Stefoni, V., Broccoli, A., Fanti, S., Pellegrini, C., Montini, G.C., Gandolfi, L., Derenzini, E., Argnani, L., Fina, M., Tucci, A., Bottelli, C., Pileri, S. & Baccarani, M. ( 2010 ) Phase II trial of short‐course R‐CHOP followed by 90Y‐ibritumomab tiuxetan in previously untreated high‐risk elderly diffuse large B‐cell lymphoma patients. Clinical Cancer Research, 16, 3998 – 4004.en_US
dc.identifier.citedreferenceAnderson, J.R., Cain, K.C. & Gelber, R.D. ( 1983 ) Analysis of survival by tumor response. Journal of Clinical Oncology, 1, 710 – 719.en_US
dc.identifier.citedreferenceCheson, B.D., Horning, S.J., Coiffier, B., Shipp, M.A., Fisher, R.I., Connors, J.M., Lister, T.A., Vose, J., Grillo‐Lopez, A., Hagenbeek, A., Cabanillas, F., Klippensten, D., Hiddemann, W., Castellino, R., Harris, N.L., Armitage, J.O., Carter, W., Hoppe, R. & Canellos, G.P. ( 1999 ) Report of an international workshop to standardize response criteria for non‐Hodgkin's lymphomas. NCI Sponsored International Working Group. Journal of Clinical Oncology, 17, 1244.en_US
dc.identifier.citedreferenceChiappella, A., Tucci, A., Castellino, A., Pavone, V., Baldi, I., Carella, A.M., Orsucci, L., Zanni, M., Salvi, F., Liberati, A.M., Gaidano, G., Bottelli, C., Rossini, B., Perticone, S., De Masi, P., Ladetto, M., Ciccone, G., Palumbo, A., Rossi, G. & Vitolo, U. ( 2013 ) Lenalidomide plus cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab is safe and effective in untreated, elderly patients with diffuse large B‐cell lymphoma: a phase I study by the Fondazione Italiana Linfomi. Haematologica, 98, 1732 – 1738.en_US
dc.identifier.citedreferenceCoiffier, B., Lepage, E., Brière, J., Herbrecht, R., Tilly, H., Bouabdallah, R., Morel, P., Van Den Neste, E., Salles, G., Gaulard, P., Reyes, F., Lederlin, P. & Gisselbrecht, C. ( 2002 ) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large‐B‐cell lymphoma. New England Journal of Medicine, 346, 235 – 242.en_US
dc.identifier.citedreferenceCox, D. ( 1972 ) Regression models and life tables. Journal of the Royal Statistical Society, 34, 187 – 220.en_US
dc.identifier.citedreferenceCrump, M., Coiffier, B., Jacobsen, E.D., Sun, L., Ricker, J.L., Xie, H., Frankel, S.R., Randolph, S.S. & Cheson, B.D. ( 2008 ) Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid) in relapsed diffuse large‐B‐cell lymphoma. Annals of Oncology, 19, 964 – 969.en_US
dc.identifier.citedreferenceFeugier, P., Van Hoof, A., Sebban, C., Solal‐Celigny, P., Bouabdallah, R., Ferm, C.A., Christian, B., Lepage, E., Tilly, H., Morschhauser, F., Gaulard, P., Salles, G., Bosly, A., Gisselbrecht, C., Reyes, F. & Coiffier, B. ( 2005 ) Long‐term results of the R‐CHOP study in the treatment of elderly patients with diffuse large B‐cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. Journal of Clinical Oncology, 23, 4117 – 4126.en_US
dc.identifier.citedreferenceFriedberg, J.W. ( 2011 ) New strategies in diffuse large B‐cell lymphoma: translating findings from gene expression analyses into clinical practice. Clinical Cancer Research, 17, 6112 – 6117.en_US
dc.identifier.citedreferenceFriedberg, J.W. ( 2012 ) Double‐hit diffuse large B‐cell lymphoma. Journal of Clinical Oncology, 30, 3439 – 3443.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
bjh12906.pdf
Size:
222.4KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.